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Received 11 May 2010; received in revised form 23 June 2010; accepted 28 June 2010Abstract Extracellular signal-regulated kinases (ERKs) have many important functions during embryogenesis. However, their
role in embryonic stem (ES) cells is controversial. Previous studies reported that, in contrast to mouse ES cells, human ES cells
differentiate if ERK1/2 is inhibited. We reexamined the role of ERK1/2 in human ES cells using a chemically defined culture
system and found that when ERK1/2 is blocked with specific chemical inhibitors, neural and mesendodermal differentiation is
prevented, but cells become sensitive to BMP-induced differentiation. Inhibition of ERK1/2 significantly reduced the
clonogenicity of human ES cells by preventing cell adhesion and survival. When this negative effect was avoided, we were able
to maintain human ES cell self-renewal for more than 3 months in the presence of ERK1/2 inhibitors in a chemically defined
culture system containing FGF2 and activin A but no BMP4. Our results suggest that the functional outcome of FGF/ERK1/2
signaling in human ES cells is influenced by the relative levels of activin A/TGFβ and BMP activity. Moreover, activation of ERK1/
2 in human ES cells is required for proper neural and mesendodermal differentiation. In contrast to mouse ES cells, a low level of
BMP4 is sufficient to initiate extraembryonic differentiation when ERK1/2 is inhibited.
© 2010 Elsevier B.V. All rights reserved.Introduction
The MAPK (Mitogen-Activated Protein Kinase) family (John-
son and Lapadat, 2002) includes ERK1/2 (ERK1 and 2), which
are activated through a chain of phosphorylation events byAbbreviations: ERK, extracellular signal-regulated kinase;
ES, embryonic stem; FGF, fibroblast growth factor; BMP, bone
morphogenetic protein; TGFβ, transforming growth factor β;
MAPK, mitogen-activated protein kinase.
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ligands, such as FGFs and EGFs, to their respective receptor
tyrosine kinases (RTKs)(Dreesen and Brivanlou, 2007). ERK1/
2 signaling has diverse roles in early embryogenesis, and
acts in a cell-context dependent manner. In preimplanta-
tion mouse embryos, the FGF–ERK1/2 pathway drives
primitive endoderm development and suppresses NANOG
expression (Chazaud et al., 2006). Prior to mouse gastrula-
tion, FGF-ERK1/2 signaling becomes highly active in
extraembryonic ectoderm and promotes the growth of
trophoblast stem cells in vitro (Corson et al., 2003; Tanaka
et al., 1998). During vertebrate gastrulation, ERK1/2
signaling is required for neural ectoderm and mesendoderm
differentiation and primitive streak formation (Ciruna and.
158 J. Na et al.Rossant, 2001; Morrison et al., 2008; Stavridis et al., 2007;
Yao et al., 2003).
In vitro, the inhibition of ERK1/2 with specific antagonists
enhances the growth of undifferentiated ES cells (Burdon et al.,
1999). Recently, it was shown that the pluripotency ofmouse ES
cells is best preserved in the presence of a combination of
inhibitors of FGF receptor tyrosin kinase, MEK1/2 (activators of
ERK1/2) and GSK3 (the “3I” condition) in a chemically defined
environment (Ying et al., 2008). The authors of that study
argued that mouse ES cells naturally exist in a meta-stable
ground state of self-renewal and that the maintenance of this
state requires inhibition of their natural tendency to differen-
tiate, which can be prevented by inhibition of specific signaling
pathways that promote their differentiation. By applying MEK1/
2 andGSK3 inhibitors and LIF, germline-competent ES cellswere
derived and propagated from refractory mouse strains, such as
the Type I diabetes NOD strain, as well as from rat embryos
(Nichols et al., 2009; Li et al., 2008). In contrast to the results
from rodent ES cells, the inhibition of FGF receptor tyrosin
kinase or MEK1/2, and therefore ERK1/2, has been reported to
lead to extraembryonic differentiation of human ES cells (Xu et
al., 2002; Pera et al., 2004; Li et al., 2007).
FGF2 activates both ERK1/2 and the PI3K–AKT path-
ways, which promotes cell proliferation, in human ES cell
culture (Dreesen and Brivanlou, 2007; Eiselleova et al.,
2009). Whereas mouse ES cells overexpressing a constitu-
tively active AKT mutant show enhanced capacity for self-
renewal and became resistant to differentiation (Watanabe
et al., 2006). As ERK1/2 is one of the multiple intracellular
effectors downstream of FGF signaling and cross talks with
other key signaling pathways, it is essential to dissect its
function under strictly defined conditions. However, most
studies of FGF2 and ERK1/2 in human ES cells have been
carried out in undefined systems, in the presence of feeder
cells, or conditioned medium, and Knockout serum re-
placement (KSR). Since the function of FGF2–ERK1/2
signaling is cell-context dependent, it is difficult to draw
definitive conclusions by comparison to the results
obtained from mouse ES cells grown under fully defined
conditions.
We have recently developed a minimal chemically
defined system, in which the effect of exogenous growth
factors and small molecules can be analysed without the
confounding influence of undefined components (Furue et
al., 2008). Using this system, we have now reexamined
the role of ERK1/2 signaling in human ES cells and found
that under defined conditions, ERK1/2 signaling permits
neural and mesendodermal differentiation of human ES
cells, but that it can also act to inhibit BMP signaling. It is
these latter effects that have led to the previous
conflicting conclusions.
Results
Inhibiting ERK1/2 prevents mesendodermal
induction in human ES cells
High concentrations of activin A (100 ng/ml) are commonly
used to induce mesendodermal lineages from human ES cells
(D'Amour et al., 2005). However, we found that it alone was
not sufficient to mediate differentiation. In HUES1 andSHEF5 cells, the addition of 10 ng/ml FGF2 is necessary to
achieve robust mesendodermal gene expression and epithe-
lial-to-mesenchymal transformation (EMT), when the cells
lost their compact colony morphology and started to spread
out (Fig. 1A). The expression of the mesendodermal genes T
(BRACHYURY), GSC (GOOSCOID), FOXA2, and SOX17 was
significantly upregulated when the cells were cultured with a
combination of 100 ng/ml activin A and 10 ng/ml FGF2 in
cells (Figs. 1B, 2A, and Supplementary Fig. 2). However,
OCT4 protein expression was maintained in cells which were
only treated with 100 ng/ml of activin A alone, whereas its
expression was diminished after the addition of FGF2, while
strong FOXA2 staining became evident in the nucleus
(Fig. 1C). We also detected stronger phosphorylation of
ERK1/2 but not AKT, associated with higher dosages of
activin A (Fig. 1D).
We employed two widely used chemical inhibitors of ERK1/
2 and PI3K, U0126 and LY294002, respectively (Bain et al.,
2007), to investigate the role of ERK1/2 and AKT signaling. For
these studies, the cells were seeded on type 1 collagen gel and
cultured in our previously described defined-medium system
hESF (Furue et al., 2008), which includes nine components,
and supplementedwith low concentrations of activin A (10 ng/
ml), hence is named hESF9A (Supplementary Table 1). When
HUES1 human ES cells were grown in hESF9A, U0126 (10 μM)
abolished the phosphorylated (activated) form of ERK1/2,
while LY294002 (10 μM) markedly reduced the phophorylated
(activated) form of AKT (Supplementary Fig. 1). The phos-
phorylation of AKT or GSK3β was not affected by U0126
(Supplementary Fig. 1).
To determine whether the activation of ERK1/2 is
responsible for the enhanced differentiation, we treated the
cells with U0126 or LY294002 for 5 days. At 1 μM, the ERK1/2
inhibitor U0126 markedly reduced cell spreading, while at 5–
20 μM, it restored the ES morphology (Fig. 2A, panels b–e),
with increased expression of OCT4 and NANOG and inhibition
of the upregulation of BRACHYURY, GSC, FOXA2, and SOX17
(Fig. 2B). At 50 μM, U0126 caused significant cell death
(Fig. 2A, panel f). By contrast, the PI3 kinase inhibitor
LY294002 did not prevent cell spreading nor recovered
expression of the pluripotency genes, OCT4 and NANOG, at
any concentration tested (Figs. 2C and D). Moreover, it
enhanced the expression of GSC, FOXA2, and SOX17 at higher
concentrations (Fig. 2D). However, at 20 μM, LY294002
showed strong cell toxicity (Fig. 2C, panel f). Taken together,
these results showed that the ERK1/2 branch of FGF2 signaling
promotes mesendodermal differentiation and, consequently,
inhibition of ERK1/2 signaling prevents human ES cells exiting
from the undifferentiated state though this route.Inhibiting ERK1/2 prevents neural differentiation
To examine whether ERK plays a role in neural differentia-
tion of human ES cells, we triggered neural differentiation by
first passaging cells in larger clumps (more than 200 cells),
with subsequent withdrawal of FGF2 and activin A from the
culture medium from the second day. Under these condi-
tions, the human ES cells adhered poorly to the substrate and
formed floating cell aggregates (Fig. 3A, panel a) in which
early neural marker genes (SIX3 and PAX6) were upregulated
(Fig. 3B). (Similar results were obtained for SHEF5 cells;
Figure 1 Addition of FGF2 led to robust mesendodermal differentiation induced by a high dosage of activin A. (A) Morphology of
HUES1 and SHEF5 ES cells cultured in 10 and 100 ng/ml of activin A with or without FGF2 after 5 days. Note that 100 ng/ml activin A
plus 10 ng/ml of FGF2 strongly induced epithelial-to-mesenchymal transition. (B) Q-PCR analysis revealed robust upregulation of
mesendodermal marker genes under these conditions. (C) Immunostaining of OCT4 (green) and FOXA2 (red) in normal HUES1 cells
treated with 100 ng/ml of activin A with or without FGF2 for 5 days. (D) A higher dosage of activin A caused stronger ERK1/2 but not
AKT phosphorylation. Karyotypically normal HUES1 cells were first cultured in hESF8 (without FGF2 and activin A) for 48 h, and then
treated with FGF2 and activin A at the indicated concentration for 30 min before Western blot analysis.
159ERK1/2 function in human embryonic stem cellsSupplementary Figs. 2C and D.) Treating the floating cell
aggregates with U0126 for 5 days improved their ability to
spread out on the substrate in a concentration-dependentmanner (Fig. 3A, panels b–d). The best concentration in this
experiment was 10 μM U0126, in which the cell aggregates
flattened out and formed compact colonies typical of
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161ERK1/2 function in human embryonic stem cellsundifferentiated ES cells (Fig. 3A, panel d). Moreover, the
upregulation of neural marker genes was inhibited (Fig. 3C).
At 20 and 50 μM, U0126 appeared to be toxic, since we
observed many vesicles emerging inside the cell and a
dramatic increase in cell death (Fig. 3A, panels e and f). We
then passaged U0126-treated and nontreated cells and
cultured them in hESF9A for 7 days. Immunostaining was
carried out to further examine the expression of OCT4, SIX3,
and PAX6. We found that without prior U0126 treatment,
cells formed “rosette-like” clusters and the expression of
OCT4 protein was markedly reduced (Fig. 3C, panel a), while
in the same cultures many rosette cells formed showing SIX3
and PAX6 nuclear staining (Fig. 3C, panels b and c). By
contrast, after U0126 treatment, HUES1 cells did not form
rosettes and maintained uniform nuclear OCT4 staining
(Fig. 3C, panel d), while SIX3 and PAX6 proteins were not
detected (Fig. 3C, panels e and f). U0126 also prevented
neural differentiation from SHEF5 cells (Supplementary
Figs. 2C and D).
ERK1/2 activation is required to counterbalance
BMP-induced differentiation in monolayer culture
Human ES cells express several BMP ligands (Sperger et al.,
2003). Moreover, the Knockout serum replacement in the
conventional human ES cell culture medium includes BMP-
like activities (Xu et al., 2005). Thus, we next tested whether
ERK1/2 activation can counteract BMP-induced differentia-
tion in human ES cells using the hESF-based monolayer
culture system. After exposure to BMP4 for 5 days, human ES
cell colonies lost their compact morphology, appearing
flattened (Fig. 4A, panel a), and also lost the expression of
the OCT4 protein (Fig. 4B, panel a). By contrast, when cells
were cultured in the presence of 50 ng/ml of FGF2 together
with BMP4, they maintained an undifferentiated morphology
as well as nuclear OCT4 expression (Figs. 4A and B, panel c).
Thus, FGF2 signaling appears to counteract the BMP
pathway. However, when U0126 was added to BMP4 in the
absence of FGF2, these flat cells appeared even earlier and
more extensively than with BMP4 alone (Fig. 4A, panel b). We
could not detect any OCT4 protein in these cells
(Fig. 4B, panel b). U0126 treatment also almost abolished
the ability of FGF2 to rescue the cells from BMP4-induced
differentiation, as many flat cells were observed under the
BMP4+FGF2+U0126 condition and OCT4 staining was absent
in most of them (Figs. 4A and B, panel d). In agreement with
the morphological changes, the RNA levels of the early
extraembryonic lineage marker AFP increased markedly in
BMP4-treated cells, but were downregulated when high
concentrations of FGF2 were added (Supplementary Fig. 3).
Cells cultured in the presence of BMP4, FGF, and U0126
showed similar upregulation of AFP as those treated with
BMP4 alone (Supplementary Fig. 3). This suggests that oneFigure 2 (A) Morphology of HUES1 ES cells cultured in activin
concentrations of U0126. Scale bar: 0.5 mm. (B) Q-PCR analysis of
compared to the levels in ES cells grown under normal serum-free c
(100 ng/ml) plus FGF2 (10 ng/ml) treated with increasing concent
marker-gene expression. Their relative expression levels were compmajor role of FGF2–ERK1/2 signaling is to suppress the
differentiation induced by BMP, which may explain the
reports that ERK1/2 inhibition promotes the differentiation
of human ES cells cultured in medium containing KSR (Xu et
al., 2002; Li et al., 2007).
ERK1/2 function is required for the attachment of
human ES cells at low cell density
In the presence of U0126, we observed a reduction in the
attachment of the human ES cells to the collagen substrate
after passaging, resulting in a high proportion of cells
floating in the media. To test the effect of U0126 on cell
attachment more easily, we used a culture-adapted HUES1
subline that carried an extra chromosome 12p, because
these cells survive better after trypsin dissociation into
single cells. In condition A, HUES1 cells cultured in hESF9A
without U0126 were dissociated into single cells and plated
at 2000 cells/cm2 density in hESF9A without U0126. In
condition B, HUES1 cells were first cultured with U0126 for
5 days; the drug was then removed 2 hours before harvesting
and the cells were plated at the same density in hESF9A
without U0126. In condition C, the cells were cultured
without U0126 but plated in hESF9A containing U0126. The
day after seeding, we found similar numbers of cells
attached to the substrate in conditions A and B, whereas
almost no cells attached in condition C (Figs. 5A and B). Thus,
ERK1/2 activity appears to be required for cell adhesion and
subsequent survival under single-cell or low-density condi-
tions. After culturing the cells for 5 days after seeding in
hESF9A, we added U0126 back into the condition B group and
maintained the cultures for a further 5 days. A high-content
screen was carried out to analyse the growth and differen-
tiation status of the cells (Figs. 5C and D). On average,
cultures maintained under conditions A and B had similar
numbers of colonies and numbers of cells per field imaged,
indicating that once cells are attached and reached a certain
density, U0126 does not affect their growth significantly.
However, there were markedly more OCT4- and SSEA4-
positive cells per field in condition B (when cells were
cultured at later stages in U0126) than in condition A,
suggesting that inhibition of ERK1/2 by U0126 reduced
spontaneous differentiation (Fig. 5D, panels a and b).
Under condition C, when cells were seeded in U0126 but
cultured without it, there were very few colonies and only a
small proportion of cells expressed OCT4 and SSEA4 (Fig. 5C,
panel c, and D condition C). We also tested the effect of
U0126 on karyotypically normal SHEF6 cells. Similar to
HUES1, U0126 significantly reduced the number of single
cells attached to the substrate and, consequently, almost no
colony formed in this group (Supplementary Fig. 4). Taken
together, these results indicate that ERK1/2 inhibition has a
negative impact on cell attachment to the substrate.A (100 ng/ml) plus FGF2 (10 ng/ml) treated with increasing
marker-gene expression. Their relative expression levels were
ulture conditions. (C) Morphology of hESCs cultured in activin A
rations of LY294002. Scale bar: 0.5 mm. (D) Q-PCR analysis of
ared to the levels in human ES cells grown in hESF9A.
Figure 3 (A) Morphology of human ES cells cultured without activin A or FGF2 treated with increasing concentrations of U0126. Scale
bar: 0.5 mm. Inset scale bar: 0.1 mm. (B) Q-PCR analysis of NANOG, SIX3, and PAX6 expression. Their relative expression levels were
compared to the levels in ES cells grown under normal serum-free culture conditions. (C) Immunostaining of OCT4, SIX3, and PAX6 (in
green) in cells first treated without (a–c) or with U0126 (10 μM) (d–f) in hESF8 for 5 days, passaged, and then cultured in hESF9A. Note
the absence of significant OCT4 staining in the absence of U0126, especially from the neural rosettes (panel a, arrows), and the
retention of OCT4 expression the presence of U0126. By contrast, note the expression of SIX3 and PAX6, especially their nuclear
localisation in the rosettes (arrows) in the absence of U0126 (panels b, c), but the absence of these transcription factors when the cells
were cultured with U0126 (panels e, f). DNA: blue. Scale bar: 100 μm.
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Figure 4 (A) Morphology of HUES1 cells cultured in different BMP4 (1 ng/ml), FGF2 (40 ng/ml), and U0126 (10 μM) combinations as
indicated on the top of each graph. Scale bar: 0.5 mm. (B) Immunostaining of OCT4 (in green) of above experiment. DNA: blue. Scale
bar: 100 μm.
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164 J. Na et al.Long-term culture of human ES cells in a chemically
defined medium containing U0126
Since U0126 can inhibit ES cell differentiation under chemi-
cally defined conditions, we assessedwhether it can be used to
support the self-renewal of several human ES cells during long-
term culture in the hESF9A medium. To reduce the adverse
effect of U0126 on cell adhesion, it was omitted from the
medium when the cells were seeded as well as the following
day; subsequently, cultures were fed with a medium contain-
ing U0126 until the next passage. After 3 passages (approx
3 weeks), three independent human ES cell lines, SHEF4,
SHEF6, and the adapted HUES1 subline, grew to produce very
large undifferentiated colonies in the hESF9A medium with
5 μM U0126 (Fig. 6A, panels a, c, and e), whereas withoutFigure 5 Inhibition of ERK1/2 prevented human ES cell attachm
attached to the substrate under different conditions (listed above ea
after passaging with or without U0126. Seeding density was 2000
different conditions (listed above each graph). (D) Bar-graph presen
per field, (c) number of colonies per well, and (d) number of cells pe
the In Cell Analyser Developer's Toolbox and the error bar is the staU0126 increased spontaneous differentiation was evident for
the SHEF4 and SHEF6 cell lines (Fig. 6A, panels b and d). The
adapted HUES1 subline also showed better colony morphology
when cultured with U0126 (Fig. 6A, panel f). After culturing in
U0126 formore than 3 months, SHEF4 and SHEF6 cells retained
a normal karyotype, while no additional karyotype changes
were detected in the adapted HUES1 line (Supplementary
Fig. 6A). The SHEF4 and SHEF6 human ES cell lines expressed
significantly higher levels of OCT4 and SSEA4 when grown in
the presence of U0126 compared to nontreated cells (Fig. 6B).
Adapted HUES1 cells displayed a less increased expression of
OCT4 and SSEA4 when grown in the presence of U0126. This
might reflect the innately different properties of individual
human ES cell lines (Fig. 6B). To confirm the specificity of
U0126, we used PD0325901, another ERK1/2 inhibitor used byent to the substrate. (A) Phase-contrast images of HUES1 cells
ch graph). (B) Bar-graph quantisation of HUES1 cell attachment
cells/cm2. (C, a–c) Immunostaining of OCT4 expression under
tation of the percentage of (a) OCT4- or (b) SSEA4-positive cells
r field. The bars represent the mean of all measured colonies by
ndard error of the mean (SEM).
165ERK1/2 function in human embryonic stem cellsYing and colleagues on mouse ES cells (Ying et al., 2008). We
found that 0.3 μM PD0325901 was sufficient to block the
phosphorylation of ERK1/2 in SHEF4 cells (Supplementary
Fig. 6A). It reduced differentiation of the SHEF4 and SHEF6 cell
lines during a period of 4 weeks (Supplementary Fig. 6B).
Human ES cells cultured in PD0325901 orU0126 for 1–3 months
retained the ability to undergo neural, mesendodermal, and
extraembryonic differentiation when appropriate inducing
conditions were applied. As shown in Supplementary Figs. 5B
and 6D, differentiated cells strongly expressed TUJ1 (neural),
BRACHYURY, FOXA2, SOX17 (mesendoderm), and CDX2 (ex-
traembryonic) and downregulatedOCT4. Our results show that
the inhibition of ERK1/2 signaling helps to prevent differen-Figure 6 (A) Morphology of human ES cells cultured for 3 passages
SSEA4 expression in human ES cells cultured with or without U0126 f
and HUES1 cells stained with P3X (negative control). The red histogtiation of human ES cells in chemically defined environments
and does not affect the pluripotency of these cells.Discussion
In this study, we analysed the function of ERK1/2 in human ES
cells under chemically defined culture conditions. Contrary
to some previous reports that inhibition of ERK1/2 causes
human ES cell differentiation (Li et al., 2007), our data
demonstrate that inhibition of ERK1/2 signaling can be
beneficial for self-renewal. Blocking ERK1/2 prevented
mesendoderm and neural induction and, consequently, thewith or without U0126 in hESF9A. (B) FACS analysis of OCT4 and
or 3 passages (3 weeks). The gray histogram is for SHEF4, SHEF6,
rams represent the experimental population.
166 J. Na et al.ES cell phenotype was retained. However, ERK1/2 activation
was needed to suppress BMP signaling under normal ES cell-
culture conditions. Human ES cells retained OCT4 expression
in the presence of a high dosage of FGF2 and 1 ng/ml of
BMP4. When ERK1/2 inhibitor U0126 was added, cells rapidly
differentiated toward an extraembryonic fate (Fig. 4). In this
respect, human ES cells appear to be fundamentally
different from mouse ES cells, as both FGF4 -/- and ERK2
-/- mouse ES cells were resistant to BMP4-induced differen-
tiation (Kunath et al., 2007). This difference could explain
why inhibition of ERK1/2 causes human ES cell differentia-
tion in a KSR-containing medium that includes BMP-like
activity (Xu et al., 2002, 2005). As the activation of ERK1/2
can suppress BMP signaling, blocking ERK in effect enhances
BMP pathway activities and, consequently, cells differenti-
ate toward extraembryonic fates. In a defined culture
system supplemented with FGF2 and activin A but no
exogenous BMP ligand, ERK1/2 is not required to suppress
BMP signaling, and since inhibition of ERK1/2 stops both
neural and mesendoderm differentiation, the cells will
remain in the undifferentiated state.
In human ES cell cultures, FGF2 appeared to carry out
some of the functions of LIF in mouse ES cells. In mice,
parallel to the STAT3–JAK pathway that upregulates KLF4
and promotes pluripotency, LIF also activates both PI3K–AKT
and MAPK1/2–ERK1/2 pathways (Niwa et al., 2009). AKT
increases the expression level of the transcription factor
TBX3, which is located upstream of the pluripotency factors
NANOG and SOX2 (Niwa et al., 2009). On the other hand, the
MAPK1/2–ERK1/2 pathway downregulates TBX3 and NANOG
to encourage lineage commitment (Niwa et al., 2009). Both
LIF and endogenously expressed FGF4 can elevate ERK
activity, which gives ES cells a tendency to initiate
spontaneous neural differentiation under serum- and feed-
er-free culture conditions (Stavridis et al., 2007; Ying et al.,
2003a). In this scenario, addition of BMP4 suppressed neural
differentiation by inducing the expression of Id proteins
through SMAD1 (Ying et al., 2003b). Blocking ERK1/2 can
prevent mouse ES cell neural differentiation and “trap” them
in the “ground state” of self-renewal (Stavridis et al., 2007;
Ying et al., 2008). In a separate study, Pluripotin, a small
molecule that inhibits both ERK1/2 and Ras-GAP, was also
able to sustain mouse ES cell self-renewal in the absence of
BMP4 in chemically defined conditions, possibly through the
same mechanism (Chen et al., 2006). Although LIF can
stimulate STAT3 phosphorylation and, therefore, its activa-
tion, in human and primate ES cells this has no detectable
effect on the pluripotency network (Daheron et al., 2004;
Sumi et al., 2004). FGF2 strongly activates both AKT and
ERK1/2. The AKT branch is critical for ES cell self-renewal.
Watanabe and colleagues showed that overexpression of a
constitutive active mutant form of AKT was able to maintain
the self-renewal of both mouse and primate ES cells
(Watanabe et al., 2006). In our experiments, inhibition of
AKT through blocking PI3K accelerated mesendodermal
differentiation of human ES cells under inducing conditions
(Figs. 2C and D). Under chemically defined conditions, we
found that ERK1/2 activation is required for proper neural
and mesendodermal lineage specification. These two impor-
tant functions seem to be conserved between human and
mouse ES cells. ERK1/2 inhibition significantly reduces
spontaneous differentiation as long as there is no BMPactivity present and so can serve as a useful strategy to
maintain human ES cell self-renewal under defined
conditions.
The interactions among ERK1/2, BMP, and TGFβ signaling
pathways are complex and may depend on the relative levels
of BMP and TGFβ signaling. It has been shown that ERK1/2
can phosphorylate the linker region of SMAD1 (a key
transducer of BMP signals), and thus lead to its cytoplasmic
retention and degradation (Fuentealba et al., 2007; Sapkota
et al., 2007). Similarly, it can either directly phosphorylate
SMAD2/3 or indirectly through other kinases such as CDK4/6,
to regulate SMAD2/3 stability and subsequently the strength
of TGFβ signaling (Schmierer and Hill, 2007). In a separate
study from our laboratory by Avery et al., in a KSR-based
medium inhibition of an activin A receptor-like kinase (ALK)
strengthened BMP signaling, as indicated by stronger
phosphorylation of the C-terminus of SMAD1/5/8 (its active
form) and the upregulation of BMP-responsive genes such as
MSX1. Knocking down SMAD4 reduced SMAD1/5/8 activation,
abolished the upregulation of differentiation genes, and
partially rescued the expression of the pluripotency genes
OCT4 and NANOG (Avery et al., 2010). This implies that
activin A/TGFβ signaling can sequester SMAD4 (the co-SMAD
essential for both BMP and TGFβ pathways) from the BMP
pathway, thus in effect attenuating the strength of the BMP
activity. FGF2–ERK1/2 enhances activin A signaling and, in
turn, antagonises BMP signaling and the associated extra-
embryonic lineage differentiation. BMP4 is also reported to
induce mesoderm differentiation from EBs (Takei et al.,
2009). In this circumstance, the cell–cell interaction and the
spatial organisation of the EBs may also have an impact on
cell signaling and fate decisions.
MAPK–ERK1/2 signaling cascades also play critical roles in
cell adhesion. In our experiments, U0126 markedly reduced
cell attachment during passaging and prevented EMT during
induced mesendodermal differentiation. Two recent pub-
lications showed that inhibition of FGF signaling affected
human ES cell adhesion, which resulted in the upregulation
of caspase 3 and anoikis, while a high concentration of FGF2
increased human ES cell clonogenicity and reduced the
number of cells floating up in the culture (Eiselleova et al.,
2009; Wang et al., 2009). ROCK inhibitor Y27632 could not
rescue the reduction in cell adhesion caused by ERK1/2
inhibition (Supplementary Fig. 4). ERK1/2 inhibition is
particularly detrimental to human ES cells when they are
at low density. This is likely because cells are more
dependent on the survival signal provided by cell–substrate
adhesion. We noted that, as human ES cells grew to higher
density, U0126 or PD0325901 treatment no longer impairs
cell survival as much. Thus, close cell–cell contact must send
out additional prosurvival signals. One of the candidate
pathways is Notch signaling. RNAi knocking down of NOTCH1
and 2, or their canonical effector CBF-1, or blocking Notch
signaling with the γ-secretase inhibitor L-685,458 all
markedly reduced the growth of human ES cells (Fox et al.,
2008). It has been shown that the engagement Notch
receptor led to the activation of AKT, the transcription
factor STAT3, and mammalian target of rapamycin to
promote the survival of stem cells (Androutsellis-Theotokis
et al., 2006). E-cadherin-mediated cell adhesion has also
been shown to activate AKT though PI3K to stimulate
epithelial cell growth (Pece et al., 1999). Therefore, cell–
167ERK1/2 function in human embryonic stem cellscell contact-dependent AKT activation may be able to
compensate for the detrimental effect caused by ERK1/2
inhibition in human ES cells once they reach a certain
density.
Based on our results, we propose that ERK1/2 plays
multiple important roles in human ES cells (Fig. 7): it is
required for neural and mesendoderm induction and essen-
tial for cell attachment to the substrate; however, it can
suppress BMP signaling and prevent extraembryonic differ-
entiation. Our model could explain the discrepancies
regarding the roles of FGF2 and ERK1/2 in human ES cells
and mouse ES cell self-renewal. Further dissecting the
“balancing action” among FGF, BMP, and activin A/TGFβ
pathways under chemically defined conditions will offer
insights into how these developmental signals regulate
mammalian ES cell fate decisions.Materials and methods
Cell lines and maintenance
HUES1 (normal and adapted), SHEF4, SHEF5 and SHEF6
human ES cells were used in this study. SHEF4, SHEF5, and
SHEF6 cells were maintained on feeders in an ES medium
containing KO-DMEM (Invitrogen) supplemented with nones-
sential amino acids, 0.1 μM 2-mercaptoethanol, 1 mM gluta-
mine, 20% serum replacement (Invitrogen), and 4 ng/ml
FGF2 (Peprotech) (Amit et al., 2000). HUES1 cells were
maintained on feeders in an HUES1 medium containing KO-
DMEM supplemented with nonessential amino acids, 0.1 mM
2-mercaptoethanol, glutamine, 8% serum replacement, 8%
plasminate (Bayer), and 4 ng/ml FGF2 (Cowan et al., 2004).
In both cases, the cells were cultured at 37 °C in a humidified
atmosphere of 5% CO2 in air. The cells were passaged with
1 mg/ml collagenase IV (Invitrogen) (for SHEF lines) and
0.05% trpsin/0.04% EDTA (Sigma) (for HUES1), respectively.
The cells were seeded onto a 25 cm2 flask (NUNC) that had
been previously coated with 0.1% porcine gelatin (Sigma) and
mitomycin C (Sigma)-inactivated MEF as feeder cells.Figure 7 Model depicting multiple roles of ERK1/2 in human
ES cells. FGF2 activated both AKT and ERK1/2. ERK1/2 promotes
neural and mesendodermal (together with a high dosage of
activin A/TGFβ) differentiation from ES cells while it suppresses
BMP-induced extraembryonic lineage differentiation. It is also
needed for human ES cell attachment to the substrate, which is
essential for ES cell survival and proliferation.Human ES cell culture in serum-free, feeder-free,
and chemically defined medium
Prior to growth-factor-treatment experiments, human ES
cells were grown for more than 3 passages in the absence of
feeders in a serum-free and chemically defined medium on
type I collagen gel (Nita Gelatin, Japan) (Furue et al., 2008).
The hESF basal medium was purchased from the Cell Science
& Technology Institute Inc., Sendai, Japan. The components
of hESF8, 9, and 9A are listed in Supplementary Table 1.
Because cells are very sensitive to the passaging strategy
used, including the size of colonies that are passaged, the
addition of activin A permits the maintenance of more robust
and reproducible cultures of undifferentiated cells. Thus,
hESF9A containing 10 ng/ml of FGF2 and activin A each was
used for regular serum-free culture. Before the start of each
series of experiments, when necessary, manual passaging
was used to ensure a uniform undifferentiated starting cell
population for all treatment groups.
Growth-factor treatment and differentiation
protocols
Serum-free, feeder-free cultured human ES cells were
seeded in 12-well plates at a density of 4×104/well. One
day after seeding, the cells were washed with an hESF8
medium, and then fed with hESF8 and with activin A (R&D
systems), BMP4, and FGF2 (Peprotech) added at the desired
concentrations. The medium was changed every 2 days with
freshly added growth factors. Cells were collected after
5 days and analysed. For neural differentiation, we used a
protocol modified from Zhang et al. (2001). Briefly, SHEF4
and SHEF6 cells were first cultured as floating EBs in hESF8
with 4 ng/ml of FGF2 for 1 week. These EBs were then plated
in 6-well plates coated with poly-L-ornithine hydrobromide
(PLOH) and 2 μg/cm2 Laminin (LN) (Sigma) and fed with
hESF8 and 20 ng/ml of FGF for 1 week. Afterward, colonies
with neural rosette morphology were manually picked and
cultured in suspension in the same medium for another
7 days. These rosettes were replated on a PLOH/LN surface
for 7–10 days. Rosettes with extensively long neurites were
picked and dissociated to obtain a relatively pure population
of neuronal cells. To initiate mesendodermal or extraem-
bryonic differentiation, cells were treated with 100 ng/ml
activin A plus 10 ng/ml FGF2 or 10 ng/ml of BMP4 on 2 μg/
cm2 FN-coated surface for 7 days.
Antibodies and chemical inhibitors
The following antibodies were used in this study: SMAD4,
OCT4, ERK1/2, and BRACHYURY (Santa Cruz); CDX2, FOXA2,
NANOG, and SOX17 (R&D systems); SIX3 (a rabbit polyclonal
antibody raised against polypeptide RLQ HQA IGP SGM RSL
AEP GC which corresponds to the C terminus of mouse SIX3;
the same sequence was present in human SIX3); PAX6 and
FORSE1 (Developmental Studies Hybridoma Bank, IA, USA);
phospho-ERK1/2, phospho-AKT, phospho-GSK3β, total GSK3 β
(Cell Signaling); SOX2 and actin (Abcam, Cambridge UK).
The monoclonal antibody to SSEA4 was produced from a
culture of hybridoma 813-70 (Kannagi et al., 1983). The
chemical inhibitors U0126, LY294002, and PD0325901 were
168 J. Na et al.purchased from Promega, Merck, and AXON Medchem
(Groningen, the Netherlands), respectively.
Western blot
For Western blot analysis, HUES1 cells were first cultured in
hESF9A for 48 h and then washed briefly with PBS and cultured
in hESF8 (without FGF andactivinA) for 48 h.Afterward, 10 ng/
ml of FGF2 and chemical inhibitors (U0126 10 μM, LY294002
10 μM, PD0325901 0.3 μM, or DMSO only) were added, while
30 min later cells were detached and lysed on ice in a sample-
loading buffer (0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol,
PhosSTOP (Roche), and 0.002% bromophenol blue). The
amount of 2×105 cells-equivalent lysate was loaded per lane.
Quantitative PCR
Total RNA was extracted with TRIZOL (Invitrogen). The
amount of 1 μg RNA of each sample was used for reverse
transcription (20 μl) using Superscript III (Invitrogen). Q-PCRs
were performed using SYBR Green JumpStart Taq ReadyMix
(Sigma-Aldrich) in an iCycler (Bio-Rad). Each gene was done
in triplicate (Fig. 1) or duplicate (Figs. 2 and 3). The sample
input was normalised against the Ct (critical threshold) value
of the housekeeping gene GAPDH. Relative quantification of
each gene was performed using the iCycler Excel program.
The error bar is the standard deviation of the Ct value.
Primer sequences are listed in Supplementary Table 2.
Immunostaining, FACS, and high-content screen
For in situ immunostaining and high-content screen, cells
were fixed in 6-well plates with 4% PFA in PBS. OCT4 and
SSEA4 staining was scanned in an In Cell Analyser 1000
(Amersham Biosciences) and analysed using the Developer's
Toolbox. OCT4, SIX3, and PAX6 staining was imaged with an
Olympus FV1000 confocalmicroscope. For FACS analysis, cells
were incubated with 0.05% trypsin in 0.2% EDTA in 37 °C, 10%
CO2 incubator until most dissociated into single cells. Trypsin
inhibitor (Sigma T6522) (1 mg/ml in DMEM) was immediately
added to inactivate the trypsin. Cells were subsequently
rinsed off the flask or 6-well plate with an hESF8 medium,
centrifuged down, and washed 3 times in PBS containing
4 mg/ml polyvinylpyrrolidone (Sigma) to prevent them from
sticking together. They were fixed in 4% PFA in PBS 0.1%
Tween 20 (PBST) for 20 min at room temperature. For
intracellular staining of Oct4, 0.2% Triton X-100 was included
in the fixative. Afterward, cells were washed 3 times in PBST,
blocked with 5% FBS–PBST for 1 h, and incubated with the
desired primary and secondary antibodies. FACS was done
using a DAKO Cytomation CyAnADP machine.
Y27632 treatment and clonogenicity assay
SHEF6 cells were dissociated into single cells as described
above and seeded at 10,000 cells/cm2 in FN (2 μg/cm2)
coated 6-well plates in hESF9A. Y27632 (10 μM) or U0126
(10 μM) was added 2 h prior to passaging and overnight
during seeding as described in Watanabe et al. (2007). The
medium was replaced the next day. Cells were grown inhESF9A for another 10 days, then fixed briefly, and stained
with alkaline phosphatase (AP) Red Substrate Solution
(Sigma). AP-positive colonies were photographed and
counted.
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